Chapter 3 · Module 4 of 4 · Pharmacodynamics

Clinical Pharmacodynamics

High-risk pharmacodynamic drug interactions, tolerance versus dependence versus addiction, cross-tolerance, and pharmacogenomic sources of pharmacodynamic variability

Three pharmacodynamic interaction patterns demand systematic vigilance: QT prolongation from potassium channel-blocking drugs (additive risk with each combination; corrected QT >500 ms warrants drug hold), additive respiratory depression from opioids combined with benzodiazepines or gabapentinoids (managed at the brainstem, not by plasma levels), and the triple whammy (NSAIDs + ACE inhibitor/ARB + diuretic), which simultaneously removes three protective mechanisms for glomerular filtration rate
Tolerance, physical dependence, and addiction are mechanistically distinct: tolerance is reduced drug effect at the same dose; physical dependence is a physiological adaptation producing withdrawal on discontinuation; addiction is compulsive drug-seeking despite harm — neither tolerance nor dependence is equivalent to addiction, and neither is an inevitable consequence of appropriate opioid prescribing
Cross-tolerance occurs when tolerance to one drug reduces sensitivity to others sharing the same receptor; opioid cross-tolerance is clinically incomplete — the basis for opioid rotation; benzodiazepine/alcohol cross-tolerance at the GABA-A receptor means alcohol-dependent patients require higher benzodiazepine doses for withdrawal management
Pharmacodynamic pharmacogenomics: VKORC1 promoter variants reduce target enzyme expression, increasing warfarin sensitivity independent of CYP2C9 metabolism — together these explain 35–50% of warfarin dose variance; beta-1 adrenergic receptor polymorphisms alter the magnitude of beta-blocker response in heart failure
SCN1A loss-of-function mutations (Dravet syndrome) cause a pharmacodynamic paradox: sodium channel-blocking antiepileptics (carbamazepine, phenytoin, lamotrigine) worsen seizures by further suppressing already-compromised inhibitory interneurons — genetic testing before prescribing in infantile fever-triggered epilepsy is now standard

Section 1 — High-Risk Pharmacodynamic Drug Interactions

Section 1

Three Interaction Patterns Requiring Systematic Vigilance

Cardiac Interaction

QT Prolongation → Torsades de Pointes

Drugs block cardiac potassium channels → delayed repolarization → prolonged QT
Corrected QT >500 ms: high TdP risk — hold offending drug
Two QT-prolonging drugs = additive prolongation
Risk factors: female sex, hypokalemia, hypomagnesemia, bradycardia, congenital long QT
Classes: antiarrhythmics, macrolides, fluoroquinolones, azoles, antipsychotics, methadone
Management: baseline ECG; correct electrolytes; monitor corrected QT

CNS Interaction

Additive Respiratory Depression

Opioids + benzodiazepines: synergistic respiratory depression at brainstem
FDA black box warning (2016)
Gabapentinoids add further respiratory depression with opioids
Alcohol potentiates both classes
Cannot be managed by monitoring plasma levels alone — effect at tissue
Co-prescribe naloxone for at-risk patients

Renal Interaction

Cumulative Nephrotoxicity

Aminoglycoside + vancomycin: synergistic proximal tubule injury; daily creatinine monitoring required
Triple whammy: NSAID + ACE inhibitor or ARB + diuretic
Simultaneously removes three compensatory mechanisms for maintaining GFR
High AKI risk in elderly and chronic kidney disease patients

Section 2 — Tolerance, Dependence, and Addiction

Section 2

Three Distinct Concepts — Often Conflated, Always Distinct

Concept	Definition	Examples	Clinical Implication
Tolerance	Reduced drug effect at the same dose; higher dose needed for same response	Opioid analgesics, benzodiazepines, nitrates, beta-agonists	Dose escalation required; not a sign of addiction
Physical Dependence	Withdrawal syndrome on abrupt discontinuation; physiological adaptation of cells	Opioids, benzodiazepines, beta-blockers, glucocorticoids, clonidine	Taper gradually; do not confuse with addiction
Addiction	Compulsive drug-seeking despite adverse consequences; neurological disorder of reward circuits	Can occur with or without tolerance or dependence	Not an inevitable consequence of opioid prescribing for pain; requires separate evaluation

Cross-Tolerance

Tolerance to one drug reduces sensitivity to others in the same class sharing the same receptor. Opioid cross-tolerance: patients on chronic high-dose opioids require higher doses of all opioids including for surgical analgesia. Cross-tolerance is incomplete between individual opioids — the basis for opioid rotation to improve analgesia. Benzodiazepine/alcohol cross-tolerance at the GABA-A receptor: alcohol-dependent patients need higher benzodiazepine doses for withdrawal management (e.g., lorazepam for delirium tremens).

Section 3 — Pharmacogenomics and Pharmacodynamic Variability

Section 3

Target Variants That Alter Drug Response

Anticoagulation

VKORC1 Polymorphism and Warfarin

VKORC1 = warfarin's target enzyme (vitamin K cycle)
Promoter variant: less enzyme expression → more sensitive to warfarin
Variant allele more common in East Asian populations → typically lower dose needed
Combined with CYP2C9 (PK) explains 35–50% of warfarin dose variance
FDA-approved genotype-based dosing guidance available

Heart Failure

Beta-1 Receptor Polymorphism

More active receptor variant: stronger response to beta-blockade
Greater heart rate reduction, blood pressure lowering, heart failure benefit
Less active variant: blunted response; may need higher beta-blocker doses
Routine genotype testing not yet standard; dosing based on hemodynamic response

Paradoxical Pharmacodynamics

SCN1A and Dravet Syndrome

SCN1A mutation: loss-of-function in inhibitory interneuron sodium channels
Paradox: sodium channel blockers WORSEN seizures in Dravet syndrome
Mechanism: further suppress already-compromised inhibitory interneurons
Carbamazepine, phenytoin, lamotrigine: contraindicated
Use instead: valproate, clobazam, fenfluramine, cannabidiol
SCN1A testing now standard in infantile fever-triggered epilepsy

Chapter 3 Complete · Pharmacodynamics

This chapter built the quantitative and mechanistic framework for understanding what drugs do to the body. Drug-receptor interactions — spanning the four receptor superfamilies, affinity and dissociation kinetics, agonist types, and antagonist mechanisms — provide the molecular vocabulary for every drug class. Emax, EC50, receptor reserve, and the therapeutic index translate that vocabulary into the clinical language of dose selection and monitoring.

Signal transduction (the G protein pathways and their second messengers), receptor regulation (desensitization, downregulation, and tachyphylaxis), and the clinical consequences of withdrawal fill in how chronic drug exposure reshapes cellular responsiveness over time. Clinical pharmacodynamics brings these concepts to the bedside: high-risk interaction patterns, the tolerance/dependence/addiction triad, and pharmacogenomic target variants each represent direct applications of receptor pharmacology to patient safety.

The pharmacokinetics chapter that follows addresses the complementary question — how the body handles the drug — and together these two chapters form the complete foundational framework that applies to every drug class in clinical pharmacology.

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th edition	McGraw-Hill, 2021
Brunton LL, Knollmann BC, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th edition	McGraw-Hill, 2023
Roden DM	Drug-induced prolongation of the QT interval	New England Journal of Medicine, 2004; 350(10):1013–1022
Nachimuthu S, Assar MD, Schussler JM	Drug-induced QT interval prolongation: mechanisms and clinical management	Therapeutic Advances in Drug Safety, 2012; 3(5):241–253
Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS	Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study	BMJ, 2015; 350:h2698
Schetz M, Dasta J, Goldstein S, Golper T	Drug-induced acute kidney injury	Current Opinion in Critical Care, 2005; 11(6):555–565
Christie MJ	Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction	British Journal of Pharmacology, 2008; 154(2):384–396
Liggett SB	Pharmacogenomics of beta-1-adrenergic receptor polymorphisms in heart failure: a paradigm for the genetics of therapeutic targets	Pharmacogenomics, 2004; 5(3):281–292
Johnson JA, Cavallari LH	Warfarin pharmacogenetics	Trends in Cardiovascular Medicine, 2015; 25(1):33–41
Kwan P, Brodie MJ	Neurological channelopathies: genetic disorders of altered ionic channels	Lancet Neurology, 2002; 1(3):178–188